Jayne S. Gurtler

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Luc Dirix, István Takács, Guy Jérusalem et al. · Breast Cancer Research and Treatment · 2017 · 756 citations · Full text

Medicine, Oncology, Pharmacology +17

Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy.

James L. Gulley, David R. Spigel, Karen Kelly et al. · Journal of Clinical Oncology · 2015 · 94 citations

Medicine, Oncology, Pharmacology +17

Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study.

Karen Kelly, Manish R. Patel, Jeffrey R. Infante et al. · Journal of Clinical Oncology · 2015 · 34 citations

Pharmacy, Oncology, Pharmacotherapy +17

A phase 2, single‐arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy

Jorge A. García, Gary R. Hudes, Toni K. Choueiri et al. · Cancer · 2014 · 33 citations

Medicine, Oncology, Pharmacology +17

Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors

John F. Deeken, Brian Shimkus, André Liem et al. · Cancer Chemotherapy and Pharmacology · 2013 · 16 citations

Medicine, Oncology, Pharmacology +12